News · 26 weeks84-24%
2025-12-282026-06-21
Mix4490d
- Insider21(48%)
- SEC Filings10(23%)
- Other8(18%)
- Leadership2(5%)
- Earnings2(5%)
- Analyst1(2%)
Latest news
25 items- INSIDERChief Patient Officer Williams Laura A exercised 31,000 shares at a strike of $0.99 and sold $490,487 worth of shares (81,898 units at $5.99) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 378,195 units (SEC Form 4)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERDirector Parsey Merdad was granted 26,455 shares, increasing direct ownership by 46% to 83,746 units (SEC Form 4)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERDirector Rodgers Richard J was granted 26,455 shares, increasing direct ownership by 6% to 439,998 units (SEC Form 4)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERDirector Mott David M was granted 46,737 shares, increasing direct ownership by 1% to 3,349,655 units (SEC Form 4)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERDirector Cadoret-Manier Onaiza was granted 26,455 shares, increasing direct ownership by 17% to 178,156 units (SEC Form 4)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERDirector Bhanji Muna was granted 26,455 shares, increasing direct ownership by 19% to 163,808 units (SEC Form 4)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERDirector Bertrand William C Jr was granted 38,800 shares, increasing direct ownership by 13% to 329,507 units (SEC Form 4)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERDirector Bazemore Robert B was granted 26,455 shares, increasing direct ownership by 64% to 68,006 units (SEC Form 4)4 - ARDELYX, INC. (0001437402) (Issuer)
- SECArdelyx Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ARDELYX, INC. (0001437402) (Filer)
- INSIDERPresident & CEO Raab Michael exercised 20,833 shares at a strike of $0.99 and sold $236,346 worth of shares (41,666 units at $5.67) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,699,200 units (SEC Form 4)4 - ARDELYX, INC. (0001437402) (Issuer)
- SECAmendment: SEC Form 144/A filed by Ardelyx Inc.144/A - ARDELYX, INC. (0001437402) (Subject)
- ANALYSTLadenburg Thalmann resumed coverage on Ardelyx with a new price targetLadenburg Thalmann resumed coverage of Ardelyx with a rating of Buy and set a new price target of $16.00
- SECSEC Form 144 filed by Ardelyx Inc.144 - ARDELYX, INC. (0001437402) (Subject)
- SECSEC Form DEFA14A filed by Ardelyx Inc.DEFA14A - ARDELYX, INC. (0001437402) (Filer)
- INSIDEROfficer Reilly Joseph James sold $23,309 worth of shares (3,719 units at $6.27), decreasing direct ownership by 1% to 149,836 units (SEC Form 4) (withholding tax)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERChief Financial Officer Hohenleitner Susan sold $9,119 worth of shares (1,455 units at $6.27), decreasing direct ownership by 0.63% to 229,078 units (SEC Form 4) (for withholding tax)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDEROfficer Bishop John E sold $14,453 worth of shares (2,306 units at $6.27), decreasing direct ownership by 0.68% to 336,845 units (SEC Form 4) (tax liability)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERChief Human Resources Officer Brady James Parker sold $11,570 worth of shares (1,846 units at $6.27), decreasing direct ownership by 0.70% to 261,066 units (SEC Form 4) to satisfy tax liability4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERChief Commercial Officer Foster Eric Duane sold $50,127 worth of shares (7,998 units at $6.27), decreasing direct ownership by 2% to 417,972 units (SEC Form 4) to satisfy withholding obligation4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERChief Business Officer Kelliher Mike sold $45,427 worth of shares (7,248 units at $6.27), decreasing direct ownership by 2% to 357,418 units (SEC Form 4) to cover withholding tax4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERChief Patient Officer Williams Laura A sold $43,804 worth of shares (6,989 units at $6.27), decreasing direct ownership by 2% to 429,093 units (SEC Form 4) (withholding obligation)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERPresident & CEO Raab Michael sold $343,133 worth of shares (54,748 units at $6.27), decreasing direct ownership by 3% to 1,720,033 units (SEC Form 4) (withholding obligation)4 - ARDELYX, INC. (0001437402) (Issuer)
- SECSEC Form 144 filed by Ardelyx Inc.144 - ARDELYX, INC. (0001437402) (Subject)
- SECSEC Form 144 filed by Ardelyx Inc.144 - ARDELYX, INC. (0001437402) (Subject)
- SECSEC Form DEFA14A filed by Ardelyx Inc.DEFA14A - ARDELYX, INC. (0001437402) (Filer)
ARDX FAQ
7 questionsWhat does Ardelyx Inc. do?
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of...Where does ARDX stock trade?
Ardelyx Inc. (ARDX) is listed on NASDAQ.What sector and industry is ARDX in?
Ardelyx Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Ardelyx Inc. go public?
Ardelyx Inc. (ARDX) completed its IPO in 2014.What are analysts saying about ARDX?
Ardelyx Inc. has had 8 recent analyst actions on file. The most recent action was from Ladenburg Thalmann: Buy with a $1600.00 price target on 2026-06-16. Recent price targets range from $550.00 to $1600.00.What companies are similar to ARDX?
Notable peers in the same industry include KDNY (Chinook Therapeutics Inc.), AKBA (Akebia Therapeutics Inc.), ZSAN (Zosano Pharma Corporation). Compare ARDX side-by-side with any of them on Quantisnow.How can I track ARDX on Quantisnow?
Quantisnow aggregates Ardelyx Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARDX to receive live email and push alerts on every new disclosure.